Eli Lilly and

Ultime notizie

Titoli nella lingua originale della fonte.

• 
  Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal (si apre in una nuova scheda)

  2 ott 2026

• 
  Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker (si apre in una nuova scheda)

  2 ott 2026

• 
  3 drug targets pharma is betting on next (si apre in una nuova scheda)

  2 ott 2026

• Correction: Top Midday Decliners (si apre in una nuova scheda)

  2 ott 2026

• 
  LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies (si apre in una nuova scheda)

  2 ott 2026

• How Has Pfizer's Story Changed? (si apre in una nuova scheda)

  2 ott 2026

• Twist Bioscience (TWST) Stock Could Be Reasonable On Its 9x Three Year Run (si apre in una nuova scheda)

  2 ott 2026

• Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? (si apre in una nuova scheda)

  The Motley Fool · 1 ott 2026

• Eli Lilly Q2 2026: Mounjaro Revenue Surge, Geographic Pricing Dynamics, and Market Share Leadership (si apre in una nuova scheda)

  AlphaStreet · 1 ott 2026

• Eli Lilly (LLY) Posts Strong Late Stage Obesity And Diabetes Trial Results (si apre in una nuova scheda)

  Simply Wall Street · 1 ott 2026

• Could Eli Lilly's Newest Weight Loss Strategy Pay Off for Decades? (si apre in una nuova scheda)

  1 ott 2026

• eli lilly and novo nordisk will discount their weight-loss drugs (si apre in una nuova scheda)

  polskieradio.pl · 1 ott 2026

• Sector Update: Healthcare Stocks Fall Late Afternoon (si apre in una nuova scheda)

  1 ott 2026

• Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs (si apre in una nuova scheda)

  1 ott 2026

• How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market (si apre in una nuova scheda)

  1 ott 2026

• Top Midday Decliners (si apre in una nuova scheda)

  1 ott 2026

• Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says (si apre in una nuova scheda)

  1 ott 2026

• Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal (si apre in una nuova scheda)

  1 ott 2026

• 3 takeaways from a European obesity scientific meeting (si apre in una nuova scheda)

  1 ott 2026

• AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment (si apre in una nuova scheda)

  1 ott 2026

• ‘Inside the NBA’ presented by Eli Lilly: 2026-27 regular season schedule (si apre in una nuova scheda)

  ESPN Press Room · 1 ott 2026

• Lilly, Foghorn part ways; Wave’s FDA-approved plans (si apre in una nuova scheda)

  1 ott 2026

• What Is The Options Market Telling Us About Eli Lilly Stock? (si apre in una nuova scheda)

  1 ott 2026

• Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win (si apre in una nuova scheda)

  Zacks · 1 ott 2026

• ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? (si apre in una nuova scheda)

  Zacks · 1 ott 2026

• The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind (si apre in una nuova scheda)

  The Wall Street Journal · 1 ott 2026

• Eli Lilly (LLY) Suffers a Larger Drop Than the General Market: Key Insights (si apre in una nuova scheda)

  Yahoo Finance · 30 set 2026

• 700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3 (si apre in una nuova scheda)

  24/7 Wall St. · 30 set 2026

• Eli Lilly Diabetes Drug Spurs Record Weight Loss in Trials (si apre in una nuova scheda)

  Newser · 30 set 2026

• Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug (si apre in una nuova scheda)

  Investor's Business Daily · 30 set 2026